We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Advises Clinical Trials on COVID-19 Contingency Measures
FDA Guidance Advises Clinical Trials on COVID-19 Contingency Measures
Protocol changes and deviations may be unavoidable to ensure the safety of trial participants during the COVID-19 crisis, the FDA says in a rare direct-to-final guidance released yesterday, and sponsors and investigators should examine alternatives to face-to-face trial procedures.